Century Therapeutics, Inc. Common Stock
IPSCCentury Therapeutics, Inc. (IPSC) is a biotechnology company focused on developing allogeneic cell therapies for solid tumors and hematologic cancers. Leveraging its proprietary platform, Century aims to create off-the-shelf, living medicines using induced pluripotent stem cell (iPSC) technology to address unmet medical needs in cancer treatment.
Company News
The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I in...
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action...
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runwa...
Century Therapeutics reported Q1 2026 financial results with $217.0 million in cash runway extending into 1Q 2029. The company's lead program CNTY-813, an iPSC-derived islet therapy for type 1 diabetes, remains on track for IND submission in 4Q 2026 with initial clinical data expected in 2H 2027. CNTY-308, a CD19-targeted CAR-iT cell therapy, is ...
The iPSC-derived NK cells clinical trial pipeline is experiencing significant momentum with 12+ companies developing 15+ pipeline therapies. Key players including Century Therapeutics, Fate Therapeutics, Cartherics, and others are advancing promising candidates like CNTY-101, FT522, and CTH-401 across various clinical stages. Recent developments ...
